Moderna, Inc.
NASDAQMRNA short interest falls 25.8% over one week to 9.4% of float, driven by massive stock rally that has climbed 145% in one month.
A new long-form analysis for MRNA this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumMRNA closed September at $154.27 — a stock that has tripled in six weeks, yet still sits below where most of the analysts who just raised their targets told clients to sell. The most notable development this week was…
Snapshot as of 20 Sept 2026
MRNA has now tripled in a week, yet the short book is bigger than it was before the INTerpath-001 catalyst — and the put/call ratio just set a new 52-week high. The short-side behaviour this week is the defining…
MRNA enters the post-catalyst session in one of the most unusual positions a heavily-shorted biotech can find itself — the bear thesis has been invalidated in a single morning, but the data snapshot still largely…
MRNA arrives at its August 6 earnings report with short sellers firmly positioned, options skewing to the most defensive level of the past year, and a stock down 31% in a month — a setup that frames the print as a…
Moderna has now rallied 68% in a month to $79.77 — yet the Street's price targets remain well below the current price, and 15.6% of the free float is still short. The analyst picture this week captures the tension…
Moderna has now added 20% in a single week and 54% over the past month — yet the short base has barely moved, and the bears who built positions at much lower prices are still holding. The central tension is familiar…
Moderna has now re-rated 43% in a single month, yet the short base has not just survived the rally — it has grown through it. Short interest has climbed to 15.4% of the free float, edging up roughly 3% over the past…
Moderna has delivered one of its strongest weekly performances of the year, up 16% to $55.40, yet short sellers have barely flinched — and that contradiction is the story this week. Short interest is elevated and…
Moderna heads into Wednesday's first-quarter release with analysts freshly raising targets — yet none willing to turn bullish. The most striking feature of the run-up is the breadth and speed of analyst target upgrades…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MRNA — free to start on ORTEX.
Sign up for free →Open MRNA on ORTEX